Inclusion Criteria:

1. Age ≥ 18 years;

2. Histological prove of SCC or esophageal adenocarcinoma;

3. T1N1M0, T2N1M0, T3N0M0, T4N0M0, T3N1M0, T4N1M0, qqTqqNM1a stage, according to the TNM
system42;

4. Life expectation above 6 months;

5. Inoperable superior, medial, or distal third esophageal cancer, including GE junction
tumors, defined as type I and II tumors in the Siewert classification43 (see
Appendix B);

6. Performance status 0, 1, or 2, according to the Eastern Cooperative Oncology Group
criteria44 (ECOG) (see Appendix C);

7. Creatinine clearance ≥ 60 ml/min, according to the Cockcroft and Gault formula45
(see Appendix D);

8. Adequate body functions, indicated by

- Creatinine clearance ≥ 60 ml/min;

- Bilirubin, transaminase, alkaline phosphatase, and gamma-GT < 1,5 x the upper
limit of normal;

- leucocytes ≥ 3000/μl;

- granulocytes ≥ 1500/ μl;

- hemoglobin ≥ 9 g/dl;

- platelets ≥ 80000/ μl;

9. Adequate calorie ingestion, at the investigator's discretion;

10. He/she must have signed the informed consent form

Exclusion Criteria:

1. Previous or planned treatment of esophageal carcinoma with surgery, radiotherapy,
chemotherapy, or antineoplastic biological therapy;

2. Presence of active infection;

3. Knowledge of the presence of HIV seropositivity;

4. Presence of severe comorbidities that, in the investigator's opinion, will put the
patient at a significantly higher risk or will damage the protocol compliance;

5. Presence of a significant neurological or psychiatric disease, including dementia and
seizures, as per the investigator's judgment;

6. History of malignant neoplasm, except for adequately treated skin basal carcinoma or
SCC, and cervical carcinoma in situ;

7. Presence of peripheral neuropathy;

8. Knowledge of the presence of hypersensitivity or allergy to drugs that will be
administered in this protocol;

9. History of severe allergic reaction;

10. Pregnancy or lactation;

11. Presence of aerodigestive fistula (trachea and/or bronchia);

12. Evident presence of trachea and/or bronchia infiltration by the tumor;

13. Presence of uncontrolled hypercalcaemia ≥ 2.9 mmol/L (or grade >1, according to the
NCI-CTCAE, version 3.0).